BioSpace News Archive

Lantern Pharma today announced that the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation and Orphan Drug Designation for the company’s drug candidate LP-184 for the treatment of pediatric patients with ATRT.

MyBiotics Pharma Ltd , a clinical stage microbiome therapeutics company, today announced the successful completion of Phase I clinical trial of MBX-SD-202 whole microbiome treatment in healthy volunteers.

GenSight Biologics, a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, reported that Leber Hereditary Optical Neuropathy subjects treated with LUMEVOQ® continued to experience significantly improved vision four years after a single injection of the gene therapy.

Innovent Biologics, Inc. announced that the Hong Kong Department of Health (DH) has approved Pemazyre®.

XPhyto Therapeutics Corp. is pleased to provide an update on the integration of 3a-diagnostics GmbH into XPhyto’s German operations.

Samsung Biologics, the world’s leading contract development and manufacturing organization, announced strong financial results for the fourth quarter and record-high earnings for the fiscal year of 2021.

OBI Pharma, a Taiwan biopharma company, announced that the first patients have been enrolled in both of the Phase 2 studies of OBI-999, an antibody drug conjugate cancer therapy targeting Globo H, and OBI-3424, a prodrug targeting the enzyme aldo-keto reductase 1C3.

RadNet, Inc. reported that it has acquired two unrelated Dutch technology companies, Aidence Holding B.V., a leading radiology artificial intelligence company focusing on clinical solutions for pulmonary nodule management and lung cancer screening and Quantib B.V., a leading radiology AI and machine learning company focusing on clinical solutions for prostate cancer and neurodegeneration.

MediWound Ltd., a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, announced positive topline results from its U.S. Phase 2 clinical study of EscharEx® for the debridement of venous leg ulcers.

SQZ Biotechnologies Announces FDA Clearance of Investigational New Drug (IND) Application for SQZ-eAPC-HPV, a Novel mRNA-based Cell Therapy for the Treatment of HPV16 Positive Solid Tumors.